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1. INTRODUCTION 
Microglial cells constitute the resident immune cell 
population of the mammalian central nervous system 
(CNS). These cells monitor environmental changes and 
serve as damage sensors within the brain. Any type of 
injury or pathological process leads to activation of the 
microglia from their surveillant/resting state. In response 
to injury, microglial cells change their morphology taking 
on an ameboid appearance and then start to migrate to the 
site of injury, proliferate, produce/release several 
substances that affect pathological processes, such as pro-
inflammatory cytokines, tumor necrosis factor (TNF)-α 
and interleukin (IL)-6 or IL-12, or even phagocytose 
damaged cells or debris to maintain the brain homeostasis 
(1).  
However, excessive activation of the microglia could 
contribute to the progression of chronic neurodegenerative 
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RESUMEN: Estudios previos han mostrado un papel 
clave de las células microgliales en los procesos 
neuroinflamatorios asociados con algunas enfermedades 
neurodegenerativas, como la enfermedad de Alzheimer 
(EA). La microglía detecta varios tipos de moléculas 
difusibles que regulan el múltiple repertorio de 
funciones microgliales. Entre ellos, los nucleótidos 
extracelulares, actuando sobre los receptores P2 
microgliales, llevan a cabo un papel central. En este 
sentido, el receptor P2X7 ionotrópico ha sido 
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inflamatorias mediadas por la microglia. 
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mecanismos, tales como la liberación a través de 
conexinas o panexinas, no se puede descartar un origen 
vesicular para estos nucleótidos liberados, basándose en 
la actividad del transportador vesicular de nucleótidos 
(VNUT). 
En este trabajo hemos analizado si la expresión de 
VNUT y el receptor P2X7, así como la liberación de 
ATP, podrían modificarse en la microglía reactiva. Para 
lograr la activación de la microglía estimulamos las 
células con el lipopolisacárido (LPS). Además, 
analizamos el efecto del péptido β1-amiloide, β1-42, que 
puede activar también las células microgliales, sobre la 
expresión de VNUT y la liberación de ATP en la 
microglía. 
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diseases, though the underlying mechanisms are still 
unclear. Regarding Alzheimer’s disease (AD), this 
disorder is characterized by complex molecular and 
cellular alterations, including the development of 
extracellular amyloid-beta (Aβ) deposits, intracellular 
aggregated phosphorylated tau, dystrophic neurites, loss of 
synapses and neurons, and a prominent gliosis. The 
reactive gliosis involves alterations in morphology and 
function of microglia and astrocytes. It has long been 
recognized that Aβ neuritic plaques are surrounded by 
activated microglial cells that could contribute to Aβ 
phagocytosis and/or compaction (2, 3). In this sense, 
microglial activation could improve the AD pathology 
reducing the Aβ levels (4). However, the release of pro-
inflamatory mediators, such as cytokines or chemokines, 
from reactive microglia is thought to contribute to the 
chronic inflammatory response associated to AD, which 
has a prominent role in the progression and severity of the 
disease (5, 6).  
Nucleotides act as widespread extracellular signaling 
molecules. The physiological effects of these compounds 
are mediated through an extended family of purinoceptors 
that are classified into ionotropic P2X or metabotropic 
P2Y receptors (7, 8). Microglia express multiple P2 
receptors that differentially sense extracellular nucleotides 
and, therefore, P2 receptor-mediated microglial responses 
have received much attention (9-12). Among these 
purinoceptors, the P2X7 receptor has gained prominent 
recognition as a regulator of inflammatory responses (13). 
Microglial cells express P2X7 receptors (14, 15) which 
drive microglial activation and proliferation (16). P2X7 
receptors are overexpressed in microglial cells in the 
neuroinflammatory foci of numerous neurodegenerative 
conditions (17) and the activation of these P2X7 receptors 
is coupled to the maturation and secretion of the key pro-
inflammatory cytokine IL-1β (18), thereby triggering or 
potentiating neuroinflammation. These results lead to 
propose the use of P2X7 receptor antagonists for the 
treatment of CNS inflammation (19, 20). Interestingly, the 
P2X7 receptor seems to be also involved in the regulation 
of the processing of the amyloid precursor protein (APP) 
(21) and the in vivo inhibition of this receptor conduced to 
a reduction of the amyloid plaques in a mouse model of 
AD (22). 
Microglia sense ATP or other nucleotides by multiple 
P2 receptors after which they change in different 
phenotypes. However, it is necessary to investigate what is 
the origin of extracellular ATP in the brain under both 
physiological and pathological conditions. Microglia have 
been shown to release ATP when the cells are exposed to 
different stimuli, such as ATP or glutamate (23, 24). The 
signaling pathways that mediate the ATP release from 
microglia remain unclear, although Connexin 43 (Cx43) 
hemichannels have been shown to be involved (25). 
However, a recent work showed that microglial cells 
express the nucleotide vesicular transporter (VNUT), 
which transports cytosolic nucleotides into vesicles using a 
proton-mediated membrane potential as a driving force, 
and these cells are able to release ATP by VNUT-
dependent exocytotic mechanisms (26). 
Due to the close relationship that exists among ATP, 
the P2X7 receptor and microglial cells in inflammatory 
and neurodegenerative processes, where the extracellular 
nucleotide can have a vesicular origin, we evaluated 
whether the expression of VNUT and the P2X7 receptor, 
as well as the ATP release, could be modified in the 
reactive microglia. To achieve microglia activation we use 
the lipopolysaccharide (LPS), one of the main components 
of gram-negative bacterial cell wall, that induces 
microglial cells activation through interaction with the 
Toll-like receptor 4 (TLR4) (27). Additionally, we 
analyzed the effect of the β-amyloid peptide β1-42, which is 
able to activate and stimulate the phagocytic activity of the 
microglial cells (28), on the expression of VNUT and the 
ATP release in the microglia. 
2.  MATERIALS AND METHODS 
2.1. Cell Culture 
Primary cultures of microglial cells were performed 
according to the procedure described by (29), with some 
modifications. Briefly, the whole brain was removed 
aseptically from postnatal day 5 C57BL/6 mice and 
submitted to digestion with papain 100 U/ml 
(Worthington, Lake Wood, NJ) (previously activated in 
Earle’s Balanced Salt Solution (EBSS) buffer containing 5 
mM l-Cys and 2 mM EDTA), in the presence of 100 U/ml 
of DNAse (Worthington, Lake Wood, NJ), 1 mM CaCl2 
and 1 mM MgCl2. Then, cells were resuspended in 
Dulbecco's Modified Eagle's medium (DMEM) containing 
10% (v/v) fetal calf serum, 25 mM glucose, 2 mM 
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin 
and 2.5 µg/ml amphotericin, and they were plated in 
culture flasks at a density of 70,000 cells/cm2. Cells were 
maintained in culture until they reached confluence 
(approximately 10–12 days), replacing the medium every 
3–4 days. This procedure allows obtaining an astroglial 
culture, as neurons do not survive under such conditions. 
To separate astrocytes and microglia, flasks were shaken at 
250 rpm for 2 h at 37°C in an orbital shaker, and after that, 
the supernatant contains microglia whereas astrocytes 
remains adhered to the culture surface. Culture medium 
was then centrifuged at 200 x g for 10 min and microglial 
cells were resuspended and seeded onto culture plates. 
Treatment with the lipopolysaccharide (LPS) was 
initiated 48h after seeding and the compound was added at 
1µg/ml concentration for 24h (26). In the case of the 
treatment with β1-42, the β-amyloid peptide was prepared 
according to (30, 31) and added at a final concentration of 
5 µM for 18h. Control non-amyloidogenic β42-1 peptide 
was prepared and added under the same conditions. 
2.2. Reverse Transcription PCR and Quantitative Real-
Time PCR 
Total RNA was obtained from cultured microglia using 
a SpeedTools Total RNA Extraction kit (Biotools), 
following the manufacturer’s instructions. After 
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purification, the total RNA was quantified and 1 µg was 
reversed transcribed using M-MLV reverse transcriptase, 6 
µg of random primers and 350 µM deoxynucleotide 
triphosphates (dNTPs) (all from Thermo Fisher Scientific). 
Quantitative real-time PCR (qPCR) reactions were 
performed in final volume of 25 µl using the LuminoCt 
qPCR Ready Mix (Sigma–Aldrich), 5 µl of the cDNA 
synthesized previously and 1.25 µl of specific commercial 
TaqMan® gene expression assays for mouse: VNUT 
(Mm00805914_m1), P2X7 (Mm00440582_m1), P2Y2 
(Mm02619978_s1) and the housekeeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 
Mm99999915_g1), all from Applied Biosystems. The 
qPCR assays were carried out using a StepOnePlus Real-
Time PCR System (Applied Biosystems) as follows: 
denaturation at 95°C for 20 s, followed by 40 cycles of 
95°C for 1 s and 60°C for 20 s. The expression of each 
gene was normalized to that of the endogenous 
housekeeping gene GAPDH amplified in parallel. 
2.3. Western Blotting 
Microglial cells were lysed and homogenized for 1 h at 
4°C in lysis buffer (pH 7.4) containing 50 mM Tris-HCl, 
150 mM NaCl, 1% Nonidet P40 and CompleteTM Protease 
Inhibitor Cocktail Tablets (Roche Diagnostics GmbH). 
The cell lysate was then centrifuged at 16,000 × g for 9 
min and the supernatants collected. Protein extracts were 
resolved on 10% SDS-PAGE gels and transferred to 
nitrocellulose membranes, which were then blocked for 1h 
at room temperature (∼25°C) with 3% bovine serum 
albumin (BSA) in Tris buffered saline (TBS) (10 mM Tris, 
137 mM NaCl, 2.7 mM KCl, 5 mM Na2HPO4, 1.4 mM 
KH2PO4 [pH 7.5]) with 0.1% Tween 20. The membranes 
were probed with primary antibodies raised against VNUT 
(1:500, MBL) or P2X7 (1:1000, Alomone Labs). Antibody 
binding was detected by ECL chemiluminescence 
(Amersham GE Healthcare), and images were captured 
with ImageQuant LAS 500 (GE Healthcare Life Sciences) 
and analyzed using ImageQuant TL. 
2.4. Immunofluorescence  
Microglial cells cultured on coverslips in 35 mm dishes 
were fixed for 15 min with 4% paraformaldehyde and then 
rinsed with phosphate buffered saline (PBS) twice for 10 
min. Afterward, coverslips were blocked and 
permeabilized for 1h at room temperature with blocking 
solution (0.1% Triton X-100, 5% fetal bovine serum and 
10% bovine serum albumin in PBS). The coverslips were 
then incubated overnight at 4°C with the corresponding 
primary antibodies: rabbit anti-VNUT (1:100, MBL), 
mouse anti-Iba1 (1:300, Wako) or rat anti-CD11b (1:500, 
ThermoFisher Scientific). The following day, the cells 
were washed three times with PBS and incubated with the 
corresponding fluorescent-tagged secondary antibodies 
(Thermo Fisher Scientific) for 1h at room temperature. 
The nuclei were counterstained with 4′, 6-diamidino-2-
phenylindole (DAPI, Thermo Fisher Scientific) and the 
coverslips were finally mounted on glass slides using 
FluoroSaveTM Reagent (Calbiochem). Images were 
acquired on a Leica TCS SPE confocal microscope. 
2.5. ATP release 
Adenosine triphosphate release was measured using the 
ENLITEN® rLuciferase/Luciferin reagent (Promega). 
Microglial cells were maintained for 30 min at 37°C in 
Mg2+-free Locke’s buffer (140 mM NaCl, 4.5 mM KCl, 
2.5 mM CaCl2, 1.2 mM KH2PO4, 5.5 mM glucose and 10 
mM HEPES [pH 7.4]) containing 100 µM ARL67156, a 
competitive inhibitor of ecto-ATPases (32), and 
subsequently, 50 µl of extracellular medium was collected 
to measure the ATP levels. The samples were centrifuged 
at 600 × g for 5 min at 4°C and 10 µl of supernatant were 
transferred onto 96-well plate placed on ice. The plate was 
then situated in a FLUOstar OPTIMA Microplate 
Luminometer (BMG LABTECH GmbH) and 100 µl of 
rLuciferase/Luciferin reagent was automatically injected 
into each well at room temperature. 
2.6. Statistical Analysis 
The data shown are mean values ± standard error of the 
mean (s.e.m) and all independent experiments shown were 
reproduced 3–6 times. The figures were generated and the 
statistical analyses performed using GraphPad Prism 6 
(GraphPad Software). The results were analyzed using an 
unpaired Student’s t-tests. A p-value ≤ 0.05 was 
considered statistically significant. 
3.  RESULTS 
3.1. Effect of LPS treatment in the expression of 
purinergic receptors and VNUT in the microglia 
Microglial cells were stimulated with 1µg/ml LPS for 
24h and mRNA levels of the P2X7 receptor and VNUT 
were analyzed. In order to confirm the effectiveness of the 
treatment, mRNA levels of the purinergic P2Y2 receptor, 
which expression increases after stimulation with the 
lipopolysaccharide (33), were also measured. 
As can be observed in Figure 1, LPS treatment induced 
a significant increase in metabotropic P2Y2 receptor 
expression, whereas P2X7 mRNA levels were not 
affected. On the other hand, VNUT mRNA levels were 
significantly reduced after LPS stimulation (Figure 1A). 
The protein levels of the nucleotide vesicular 
transporter and the P2X7 receptor were also measured by 
Western blot analyses and a marked reduction in the 
amount of both proteins was observed after LPS treatment 
(Figures 1D-F). 
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Figure 1.  Effect of LPS treatment in the expression of purinergic receptors and VNUT in microglia cultures . Q-PCR 
analysis of mRNA levels of VNUT (A), P2X7 receptor (B) and P2Y2 receptor (C) after stimulation with LPS (1µg/ml) for 24h. Values are 
represented as a percentage of those obtained in untreated (control) cells, which were set as a 100%. (D) Western blot detection of VNUT 
and P2X7 proteins in cellular lysates of both LPS treated and untreated microglial cells. VNUT (E) and P2X7 receptor (F) protein levels 
were normalized with respect to β-actin. Values are represented as a percentage of those obtained in untreated cells, which were set as a 
100%. Data are the mean ± SEM of three independent experiments. **p < 0.01 (Student’s t-test). 
 
3.2. Effect of LPS treatment in the ATP release by the 
microglia 
The effect of LPS in the microglial culture was 
visualized by immunofluorescence techniques, using a 
specific marker of microglial cells, such as the Iba1 
(ionized calcium-binding adapter molecule 1) protein (34). 
As can be observed in figure 2A, microglial cells acquire 
an amoeboid morphology that is characteristic of the 
reactive microglia after 24h of treatment with the 
lipopolysaccharide, which confirmed that the LPS 
treatment was effective. Regarding the distribution of the 
nucleotide vesicular transporter, this was mainly localized 
in the proximal zone to the cell nucleus (Figure 2A). 
The release of ATP after the treatment with LPS was 
measured by luminometric techniques. As can be observed 
in Figure 2B, the treatment with the lipopolysaccharide for 
5 min induced a significant increase in the luminescence 
values, which means a higher liberation of the nucleotide 
to the extracellular medium. These results are in agreement 
with those obtained by other research groups (35). 
However, the stimulation with LPS for 24h did not 
significantly modify the recorded luminescence values 
(Figure 2C). 
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Figure 2.  Effect of LPS treatment in the ATP release by the microglia . (A) Representative photomicrographs of quiescent 
(upper panels) and LPS treated (lower panels) microglial cells showing VNUT (green) and Iba1 (red) immunodetection. Nuclei are 
counterstained with DAPI (blue). A merge image is shown. Scale bar = 15 µm. (B, C) Luminometric measure of the extracellular ATP in 
microglial cells treated with LPS for 5 min (B) or 24 h (C). Luminiscence values were normalized with respect to those obtained in 
untreated (control) cells and are represented as a percentage. Data are the mean ± SEM of three independent experiments. **p < 0.01 
(Student’s t-test). 
3.3. Effect of the amyloid peptide β1-42 in VNUT 
expression in microglial cells. Release of ATP 
Stimulation of the microglia with the amyloid peptide 
β1-42 at a 5 µM concentration for 18h resulted in a 
significant increase in the ATP release to the extracellular 
medium when compared with the effect of the non-
amyloidogenic (control) β42-1 peptide (Figure 3A). 
However, VNUT expression was unaffected by the 
treatment with the amyloidogenic peptide as both the 
mRNA and protein levels of the transporter remained 
constant in β1-42 or β42-1 treated cells (Figura 3B).  
Moreover, the treatment with the amyloidogenic 
peptide induced a morphological change in the microglial 
cells which acquired the amoeboid morphology that is 
characteristic of the reactive microglia (Figure 3C). 
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Figure 3.  Effect of the amyloid peptide β1-42 in VNUT expression in microglial  cells .  Release of ATP.  Luminometric 
measure of extracellular ATP (A) and Q-PCR analysis of the VNUT mRNA levels (B) in microglial cells treated with the control peptide 
β42-1 or the amyloidogenic peptide β1-42 for 18h. Values were normalized with respect to those obtained in cells treated with the control 
peptide and are represented as a percentage. Data are the mean ± SEM of three independent experiments. *p < 0.05 (Student’s t-test). (C) 
Representative photomicrographs of microglial cells treated with the control peptide β42-1 (upper panels) or the amyloidogenic peptide β1-
42 (lower panels) showing immunodetection for VNUT (green) and the microglial cell marker CD11b (red). Nuclei are counterstained 
with DAPI (blue). Scale bar = 10 µm. 
4.  DISCUSSION 
A common characteristic of the CNS diseases that 
courses with inflammation is that the activation of 
microglial cells occurs at the initial stages (36, 37). Then, 
cells migrate to the damaged area where they carry out 
phagocytic processes and mediate the inflammatory 
responses (1). Purinergic system plays an important role in 
the regulation of such processes, ATP being a key 
molecule in the development of microglial functions. Due 
to the relevance of the presence of extracellular ATP in the 
physiopathological context of the microglia, we asked 
whether such presence could be mediated by a VNUT-
dependent mechanism.  
Our first methodological approach was the activation 
of the microglia through the use of the lipopolysaccharide 
LPS. Stimulation with this bacterial endotoxin has been 
used as a study model for neuroinflammatory processes, 
which are present in neurodegenerative diseases (38, 39). 
The conditions of the treatment of the microglia with LPS 
were based on previous studies carried out in a microglial 
cell line (26). The effectiveness of this stimulation was 
confirmed by the morphological change observed, 
microglial cells acquiring an amoeboid morphology, as 
well as by the increase in the expression of the P2Y2 
receptor (33). LPS treatment did not modify the mRNA 
levels of the P2X7 receptor, although a significant 
reduction in the amount of the protein was observed. These 
results could reflect a change in the turnover or 
degradation of the P2X7 protein induced by the 
lipopolysaccharide. In the case of VNUT, the 24-hour 
treatment with LPS produced a significant decrease in its 
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expression both at the mRNA and protein levels. These 
data does not agree to those described in a previous study 
in which the vesicular transporter was identified in the 
microglia (26). In this case, although the conditions tested 
were the same, the authors of the work used a cell line 
instead of a primary microglial culture. Although it is a 
widely used study model, it is important to consider the 
origin of this microglial cell line, obtained from the brain 
of a transgenic mouse deficient in the p53 gene (40). The 
absence of this gene, known as the guardian of the 
genome, enhances the proliferative potential of the cells 
(41), so that the pattern of gene expression can differ 
considerably from that of the primary microglia from wild 
type animals. Likewise, in other microglial cell lines, 
discrepancies have been observed in the responses to the 
same treatment, not only with respect to the primary 
microglial culture, but also in the same cell line used (42). 
Therefore, this could explain the differences observed 
regarding the expression of VNUT. 
On the other hand, LPS caused a significant increase in 
the amount of ATP released to the extracellular medium in 
a five-minute interval, which is coincident with previous 
data obtained by other research groups (35). These results 
confirm that LPS induces the release of ATP in the 
microglia, with the initial response being very pronounced. 
However, the luminescence values recorded in LPS treated 
cells for 24 hours did not significantly differ from the 
control values. We cannot define the mechanism involved 
in LPS-induced ATP release from microglial cells. Despite 
this, the robust expression of VNUT in both LPS and 
untreated cells make possible that such release could be 
mediated at least in part by VNUT-dependent exocytotic 
mechanism. However, the decrease in transporter 
expression by treatment of the microglial cells with LPS 
suggests that another mechanism other than exocytosis, 
such as release trough connexins or panexins (25, 43), 
could mediates the ATP release from these cells. 
Our second methodological approach was based in the 
use of the amyloid peptide β1-42. Again, the microglial cells 
acquired an amoeboid morphology, similar to observed 
after LPS treatment and typical of reactive microglia, 
following stimulation with the β1-42 peptide. In this case, 
treatment with the amyloid peptide β1-42 for 18 hours did 
not alter the expression of VNUT, but produced a 
significant increase in the extracellular levels of ATP. β1-
42-induced ATP release from microglial cells has been 
described in a previous work (44). However, in this case 
acute (less than one hour) stimulation periods were used. 
Our results, however, showed long-term potentiation of 
ATP release by β1-42 peptide treatment in microglial cells. 
Although it cannot be confirmed that the release of ATP is 
mediated by a VNUT-dependent exocytotic mechanism, 
this idea cannot be ruled out, taking into account the 
expression of the transporter in the microglial cells that, 
unlike the treatment with LPS, remains unchanged in β1-42 
stimulated cells. 
It has been previously shown that microglial cells 
express the amyloid precursor protein (APP) and hence 
these cells are able to produce and release the β-amyloid 
peptide (45-47). The ATP released by the microglia in 
response to β1-42 peptide stimulation could activate 
microglial P2 receptors that in turn regulate β-amyloid 
peptide formation. It has been described that P2X7 and 
P2Y2 receptors modulate the α-secretase-dependent 
processing of the APP protein, these receptors having 
opposite effects on β-amyloid peptide generation (21). 
Activation of the P2X7 receptor leads to a reduction of α-
secretase activity which enhances the amyloidogenic 
processing of the APP and the formation of β-amyloid 
peptide. However, activation of the P2Y2 receptor 
increases α-secretase activity, thus precluding the 
generation of the β-amyloid peptide (21). As activation of 
the microglial cells lead to reduction in the expression of 
the amyloidogenic P2X7 receptor and to an increase in the 
expression of the non-amyloidogenic P2Y2 receptor, this 
could represent a negative feedback mechanism by which 
the β-amyloid peptide limits or reduces its own formation 
and secretion by the microglia. Additionally, it has been 
previously described that the nucleotides released by the 
microglia in response to β1-42 peptide stimulation enhance 
cell migration and promote β-amyloid peptide 
phagocytosis through activation of the P2Y2 receptor (44). 
However, to have a complete image of this process it is 
necessary to take also into account the effect of the 
microglial ATP release on purinergic receptors expressed 
in cells other than microglia, such as surrounding neurons 
and astrocytes.  
5.  CONCLUSIONS 
ATP and other nucleotides are important signal 
molecules that regulate a wide diversity of microglial 
functions. One of the possible sources of extracellular 
nucleotides in the CNS is their release from microglial 
cells. It has been demonstrated that microglia are able to 
release ATP and other nucleotides in response to a variety 
of stimuli. 
Our results demonstrate that activation of microglial 
cells by LPS or the β-amyloid peptide β1-42 induces an 
increase in the ATP release, measured by luminometric 
techniques. This release could be mediated, at least in part, 
by a VNUT-dependent exocytotic mechanism, as VNUT 
appear to be robustly expressed by both resting and 
reactive microglia. However, in the case of the activation 
by LPS, the reduction in the expression of the transporter 
in activated cells, suggests that a different mechanisms, 
other than exocytosis, could be also involved in the ATP 
release from these cells. 
Moreover, activation of microglial cells induces a 
reduction in the expression of the purinergic P2X7 
receptor and an increase in P2Y2 receptor expression. In 
the case of the activation by β1-42 peptide, it can be 
hypothesized that this could represent a negative feedback 
mechanism by which the β-amyloid peptide limits their 
own formation and release by microglial cells. 
Taken together, our results highlight the relevance of a 
new element, the nucleotide vesicular transporter (VNUT), 
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and its role in the ATP release, in the complex interplay 
among extracellular ATP, purinergic receptors and 
microglial cells in the context of neuroinflammatory 
responses in neurodegenerative diseases.  
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